RegenxBio (RGNX): License Agreement with Nippon Shinyaku Brings Up to $810 Million - Experts See Up to 455% Price Potential

RegenxBio Inc. (RGNX) (i.) is a leading company in the field of gene therapy, focusing on the development of innovative treatments for rare genetic disorders. The focus is on AAV therapeutics (Adeno-associated virus therapeutics). AAV therapeutics are a form of gene therapy where an adeno-associated virus (AAV) is used as a vector to deliver genetic material into a patient's cells. AAVs are viruses that do not cause disease but are used as carriers for therapeutic genes due to their ability to safely integrate DNA into cells. In gene therapy, AAV...